Phase 2 N=20 Oral Liquid 13-cis-retinoic Acid (13-CRA)
Neuroblastoma
Primary: Relative Bioavailability — 10009.0; 6075.9 (h.ng/mL)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=32 Tolerability and Immunogenicity of rBV A/B for the Production of BabyBIG®
Botulism
Primary: Proportion of Subjects Achieving Greater Than 3- or 4-Fold Increases in Neutralizing Antibody Concentration (NAC) — .844; .938; .875; .906 proportion of participants
Phase 2 N=194 Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma
Burkitt Lymphoma · Diffuse Large B-cell Lymphoma, c-MYC Positive · Plasmablastic Lymphoma
Primary: Percentage of Participants With Kaplan-Meier Curve Progression Free Survival (PFS) Constructed With an 95% Confidence Interval — 100; 82.1; 71.0 percentage of participants
N/A N=23 Multicenter Trial Evaluating Quality of Tears Produced by Nasal Neurostimulation
Dry Eye Syndromes
Primary: Fluorescein Tear Clearance With Application
N/A N=142 99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis
Differentiated Thyroid Cancer · Osteoporosis
Primary: Percent Change of Bone Mineral Density in Lumbar and Hip — 3.0; 3.2; 3.8; 5.1 percentage change
Phase 3 N=590 A Trial to Evaluate the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder
Attention Deficit Disorder · Attention Deficit Hyperactivity Disorder
Primary: Change From Baseline in ADHD Investigator Symptom Rating Scale (AISRS) Score at Day 42 — -12.1; -12.5; -8.07 score on a scale — p==0.0021
N/A N=140 A New Operation for the Treatment for Long-standing Atrial Fibrillation
Cardiovascular Disease
Primary: Numbers of Participants Free From AF — 20; 96; 20; 97 Participants
N/A N=40 Cochlear Implantation in Adults With Asymmetric Hearing Loss Clinical Trial
Hearing Loss
Primary: Change in Poor Ear Alone CNC Monosyllabic Word Understanding in Quiet — 0.09; 0.53; 0.44 percentage of words correct — p=<0.001
Phase 2 N=45 Study of Flexible Doses of the Triple Reuptake Inhibitor EB-1020 Sustained Release (SR) in the Treatment of Adult Males With Attention-Deficit Hyperactivity Disorder
Adult ADHD
Primary: Change From Baseline-2 in ADHD Symptoms to Week 4 as Assessed by the Adult Attention-Deficit Hyperactivity Disorder Rating Scale (AD HD-RS-IV) — 38.70; -21.41 score on a…
N/A N=20 Effect of Local Anaesthetic Dilution on the Characteristics of Ultrasound Guided Axillary Brachial Plexus Block
Brachial Plexus Blockade
Primary: Onset of Axillary Block — 8.75; 6.25 minutes — p=0.03
Phase 2 N=178 Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
Brain and Central Nervous System Tumors · Glioblastoma Multiforme
Primary: Median Progression-Free Survival (PFS) Comparison of Thalidomide Arms Versus no Thalidomide Arms — 7.6; 8.7 months
Phase 2 N=35 Rabbit Antithymocyte Globulin (Thymoglobuline) With Ciclosporin for Patients With Acquired Aplastic Anaemia
Aplastic Anemia
Primary: Number of Participants With Response to Rabbit Antithymocyte Globulin (Thymoglobuline) — 1; 11; 18; 3 Participants
N/A N=328 Chronic Pain Skills Study
Chronic Pain
Primary: Change From Pre-Treatment in Average Pain Intensity on a 0-10 Numerical Rating Scale Immediately Following End of Treatment (Post-Treatment) — -.57; -.61; -.85 score on…
Phase 2 N=140 A Pilot Trial to Assess Low-Intensity Ultrasound in Osteoarthritis
Osteoarthritis, Degenerative
Primary: Co-Primary Measure: a) Symptom Reduction: OMERACT-OARSI Treatment Responsiveness — 37; 38; 18; 16 Participants
Phase 1 N=56 Single Ascending Dose Study of AMG 570 in Healthy Subjects
Systemic Lupus Erythematosus
Primary: Number of Participants Who Experienced One or More Treatment-emergent Adverse Events (TEAEs) — 6; 5; 4; 4 Participants